Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara, Nancy Zhang, Ellie Corigliano et al. · Archives of Pathology & Laboratory Medicine · 2018
CONTEXT.—: Regulatory approval of pembrolizumab for treatment of gastric and gastroesophageal junction (G/GEJ) adenocarcinoma required a reproducible scoring method for use of programmed death ligand-1 (PD-L1) protein expression as a companion diagnostic to identify likely responders to therapy. OBJECTIVE.—: To develop an immunohistochemical scoring algorithm that includes PD-L1 expression for tumor and immune cells, that is, the combined positive score. DESIGN.—: Four previously treated tumor types in the KEYNOTE-012 and KEYNOTE-028 studies were analyzed descriptively with a version of the PD-L1 immunohistochemical 22C3 pharmDx assay labeled for investigational use only to determine the relative importance of PD-L1 expression in tumor versus immune cells as a biomarker for pembrolizumab response. A combined positive score was developed as a novel scoring method and was compared with the tumor proportion score in cohort 1 from the KEYNOTE-059 study (G/GEJ cancer). External reproducibility was assessed. RESULTS.—: Per combined positive score cutoff of 1 or more, the prevalence of PD-L1 expression in patients with G/GEJ cancer was 57.6% (148 of 257 patients), with reasonable enrichment of responses (odds ratio, 2.8). Per tumor proportion score cutoff of 1% or more, prevalence was 12.5% (32 of 257 patients), with minimal enrichment (odds ratio, 1.4). External reproducibility assessments demonstrated interpathologist overall agreement of 96.6% (591 of 612; 95% CI, 94.0%-98.7%) and intrapathologist overall agreement of 97.2% (595 of 612; 95% CI, 95.3%-98.9%). CONCLUSIONS.—: Combined positive score is a robust, reproducible PD-L1 scoring method that predicts response to pembrolizumab in patients with G/GEJ cancer. This novel scoring method supported US Food and Drug Administration approval of pembrolizumab as third-line therapy for G/GEJ cancer and has facilitated investigation in other indications.
Cited by 536 works. doi:10.5858/arpa.2018-0043-oa
Authors
- Karina Kulangara
- Ellie Corigliano
- Lindsay Guerrero
- Stephanie A. Waldroup
- Dipeshkumar Jaiswal
- Malinka Jansson
- Supriya Shah
- Debra Ann Hanks
- Jiangdian Wang
- Jared K. Lunceford
- Mary J. Savage
- Jonathan Wes Juco
- Kenneth Emancipator
References
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project